Skip to main content
. 2021 Jul 1;10(13):2963. doi: 10.3390/jcm10132963

Table 3.

Patients with ICC metastases treated by SMWA.

Patient Age at SMWA Gender Tumor Stage Previous Treatment Adjuvant CTX Location Metastasis Segment Size of Ablated Metastasis Complications > Dindo IIIa
1 72 W T2aN1M0 L0V0Pn1 G1 R0 ALPPS Gemcitabine II 32 no
2 37 W T1N0M1 L0V0Pn0 R0 G3 Right hepatectomy + metastectomy left liver Xeloda II 15 no
3 58 M T1N0M0 Ln1V0Pn0R1 G3 ALPPS Gemcitabine/ Capecitabine IVb 26 & 25 no
4 66 W T2N0M0 Ln0V1Pn0R1 G2 Extended left hepatectomy none VIII 17 no
5 56 M T2aN0M0 Ln0V0Pn1R0 G1 ALLPS none III 6 abscess
Patient Local Recurrence Time to Recurrence (Months) Treatment of Recurrence Death OS after SMWA (Months) OS after
Initial Diagnosis
Overall Disease Progression
1 yes 5 SBRT yes 19 45 yes
2 no no 20 34 no
3 yes 3 CTX yes 5.5 35 yes
4 no yes 6.5 15 no
5 no no 1 25 no

Gender: M = male, F = female; OS = overall survival; CTX = chemotherapy; SBRT = stereotactic body radiotherapy; ALPPS = Associating Liver Partition and Portal Vein Ligation.